JP6685432B2 - マイクロニードルデバイス - Google Patents
マイクロニードルデバイス Download PDFInfo
- Publication number
- JP6685432B2 JP6685432B2 JP2018559468A JP2018559468A JP6685432B2 JP 6685432 B2 JP6685432 B2 JP 6685432B2 JP 2018559468 A JP2018559468 A JP 2018559468A JP 2018559468 A JP2018559468 A JP 2018559468A JP 6685432 B2 JP6685432 B2 JP 6685432B2
- Authority
- JP
- Japan
- Prior art keywords
- dexmedetomidine
- coating
- microneedle
- microneedles
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011248 coating agent Substances 0.000 claims description 47
- 238000000576 coating method Methods 0.000 claims description 47
- 229960004253 dexmedetomidine Drugs 0.000 claims description 45
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 18
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 17
- 229940039009 isoproterenol Drugs 0.000 claims description 17
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 3
- 239000004201 L-cysteine Substances 0.000 claims description 3
- 229960002746 dexmedetomidine hydrochloride Drugs 0.000 description 14
- VPNGEIHDPSLNMU-MERQFXBCSA-N dexmedetomidine hydrochloride Chemical compound Cl.C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CNC=N1 VPNGEIHDPSLNMU-MERQFXBCSA-N 0.000 description 14
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 11
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000008199 coating composition Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- -1 capronolactone Polymers 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000025 natural resin Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Description
以下の例において、マイクロニードルデバイスは次のように作製した。
コーティングを形成する各成分と適当な量の精製水(及び、必要であれば、エタノール)を混和し、コーティング組成物の溶液を得た。次に、マイクロニードルの先端を溶液に浸漬して、これを風乾することで、マイクロニードル上にコーティングを形成した。浸漬は、コーティング中のデクスメデトミジン塩酸塩の量が30〜60μg程度となるように行った。
以下の例において、血漿中のデクスメデトミジン(Dex)の濃度の上昇速度は次のように分析した。
1)雄のイヌの、除毛した腹側部の皮膚にマイクロニードルデバイスを適用し、5、10、20、30、60、及び90分後に採血をした。
2)血漿中のデクスメデトミジンを、液体クロマトグラフィー質量分析法(LC−MS法)を用いて定量するとことにより、血漿中のデクスメデトミジン濃度を求めた。
3)デクスメデトミジン濃度をデクスメデトミジンの投与量で除して得られた値の経時変化から、デクスメデトミジン濃度の上昇速度を分析した。デクスメデトミジンの投与量は、コーティング中に配合したデクスメデトミジン塩酸塩の量から算出した。
以下の例において、コーティング中の各成分の、皮膚内へ移行した量は、次のようにして求めた。
1)マイクロニードルデバイスを10秒間適用した後、皮膚表面及びマイクロニードルデバイス上に残存した各成分(例えば、デクスメデトミジン塩酸塩又は血管拡張剤)を回収し、HPLC法を用いてそれぞれの量(残存量)を測定した。
2)別途、同じ構成のマイクロニードルデバイスを準備し、コーティング中の上記各成分の量(初期量)を測定した。
3)求めた初期量及び残存量から、上記各成分の皮膚内への移行量を算出した。
以下の例において、コーティング中のデクスメデトミジン塩酸塩又はイソプロテレノール塩酸塩の保存安定性は、次のようにして求めた。
1)調製後のマイクロニードルデバイスをアルミラミネート包材で密封包装した。
2)マイクロニードルデバイスの調製から3日後、HPLC法によりコーティング中のデクスメデトミジン塩酸塩又はイソプロテレノール塩酸塩の量(初期量)を測定した。
3)別途、同様にアルミラミネート包材で密封包装したマイクロニードルを準備し、50℃で1週間保存後、HPLC法によりコーティング中のデクスメデトミジン塩酸塩又はイソプロテレノール塩酸塩の量を測定した。
表1に示す成分からなるコーティングを備えるマイクロニードルデバイスを作製した。表中の「基剤」は、水溶性高分子を含む生理不活性の成分である(以下同じ)。使用したマイクロニードルアレイの仕様は次のとおりである。
材質:ポリ乳酸、マイクロニードルの形状:四角錐、マイクロニードルの長さ:500μm、マイクロニードルの配列:格子状、マイクロニードルの本数:640本、マイクロニードルの配列が基板に占める面積:約1cm2
表2に示す成分からなるコーティングを備えるマイクロニードルデバイスを作製した。使用したマイクロニードルアレイの仕様は次のとおりである。
材質:ポリ乳酸、マイクロニードルの形状:四角錐、マイクロニードルの長さ:500μm、マイクロニードルの配列:格子状、マイクロニードルの本数:156本、マイクロニードルの配列が基板に占める面積:約1cm2
表4に示す成分からなるコーティングを備えるマイクロニードルデバイスを作製した。マイクロニードルアレイは、試験例1と同様のものを使用した。
表6に示す成分からなるコーティングを備えるマイクロニードルデバイスを作製した。マイクロニードルアレイは、試験例1と同様のものを使用した。50℃で1週間保存した場合の、コーティング中のデクスメデトミジン塩酸塩の安定性を上述の方法で分析した。また、実施例7及び8については、イソプロテレノール塩酸塩の安定性についても分析した。
Claims (5)
- 基板と、基板上に配置されたマイクロニードルと、マイクロニードル上に形成されたコーティングと、を備えるマイクロニードルデバイスであって、
コーティングは、デクスメデトミジン又はその薬学的に許容可能な塩と、イソプロテレノール又はその薬学的に許容可能な塩と、を含む、マイクロニードルデバイス。 - コーティング中のデクスメデトミジン及びその薬学的に許容可能な塩の合計100質量部に対する、イソプロテレノール及びその薬学的に許容可能な塩の合計量が、0.3質量部以上である、請求項1に記載のマイクロニードルデバイス。
- コーティングがさらに安定化剤を含む、請求項1又は2に記載のマイクロニードルデバイス。
- コーティングがさらにL−システインを含む、請求項1又は2に記載のマイクロニードルデバイス。
- コーティングがさらにピロ亜硫酸ナトリウムを含む、請求項1又は2に記載のマイクロニードルデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016250998 | 2016-12-26 | ||
JP2016250998 | 2016-12-26 | ||
PCT/JP2017/046456 WO2018123982A1 (ja) | 2016-12-26 | 2017-12-25 | マイクロニードルデバイス |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018123982A1 JPWO2018123982A1 (ja) | 2019-10-31 |
JP6685432B2 true JP6685432B2 (ja) | 2020-04-22 |
Family
ID=62710451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018559468A Active JP6685432B2 (ja) | 2016-12-26 | 2017-12-25 | マイクロニードルデバイス |
Country Status (8)
Country | Link |
---|---|
US (2) | US20190350840A1 (ja) |
EP (1) | EP3560495B1 (ja) |
JP (1) | JP6685432B2 (ja) |
KR (1) | KR102274352B1 (ja) |
CN (1) | CN110114069B (ja) |
ES (1) | ES2895764T3 (ja) |
TW (1) | TWI700097B (ja) |
WO (1) | WO2018123982A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112351809B (zh) * | 2018-06-26 | 2023-07-14 | 久光制药株式会社 | 微针装置及其制造方法 |
CN116764087A (zh) * | 2018-08-15 | 2023-09-19 | 阿勒根公司 | 具有活性成分的微针阵列 |
CN110664787B (zh) * | 2019-10-15 | 2022-05-27 | 福建医科大学附属第一医院 | 右美托咪定缓释微针阵列及其制备方法 |
CN114828849A (zh) * | 2019-12-23 | 2022-07-29 | 久光制药株式会社 | 微针装置及其制造方法 |
DE102020109157A1 (de) * | 2020-04-02 | 2021-10-07 | Lts Lohmann Therapie-Systeme Ag | Trägerelement für Mikronadeln sowie Mikronadelarray-Einrichtung |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
ATE234649T1 (de) | 1996-12-20 | 2003-04-15 | Alza Corp | Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses |
WO2008001200A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
CN102112151A (zh) * | 2008-07-30 | 2011-06-29 | 久光制药株式会社 | 微针装置及由微针装置使日本脑炎病毒抗原的功效升高的方法 |
CN102300566A (zh) * | 2008-11-30 | 2011-12-28 | O·扎查尔 | 血管收缩剂的皮肤应用 |
US20120095104A1 (en) * | 2008-11-30 | 2012-04-19 | Oron Zachar | Use of vasoconstrictors |
EP2683358B1 (en) * | 2011-03-07 | 2015-06-03 | 3M Innovative Properties Company | Microneedle devices and methods |
US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
SG11201507885TA (en) * | 2013-03-22 | 2015-11-27 | 3M Innovative Properties Co | Microneedle applicator comprising a counter assembly |
CA2924231C (en) * | 2013-10-07 | 2018-04-03 | Teikoku Pharma Usa, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
EP3192556A4 (en) * | 2014-09-11 | 2018-05-09 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device |
-
2017
- 2017-12-25 EP EP17888272.6A patent/EP3560495B1/en active Active
- 2017-12-25 JP JP2018559468A patent/JP6685432B2/ja active Active
- 2017-12-25 CN CN201780080926.8A patent/CN110114069B/zh active Active
- 2017-12-25 WO PCT/JP2017/046456 patent/WO2018123982A1/ja unknown
- 2017-12-25 ES ES17888272T patent/ES2895764T3/es active Active
- 2017-12-25 US US16/473,119 patent/US20190350840A1/en not_active Abandoned
- 2017-12-25 KR KR1020197018463A patent/KR102274352B1/ko active IP Right Grant
- 2017-12-26 TW TW106145761A patent/TWI700097B/zh active
-
2022
- 2022-09-02 US US17/902,303 patent/US20220409524A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPWO2018123982A1 (ja) | 2019-10-31 |
KR20190087579A (ko) | 2019-07-24 |
EP3560495A4 (en) | 2020-08-05 |
US20220409524A1 (en) | 2022-12-29 |
KR102274352B1 (ko) | 2021-07-06 |
WO2018123982A1 (ja) | 2018-07-05 |
US20190350840A1 (en) | 2019-11-21 |
TWI700097B (zh) | 2020-08-01 |
ES2895764T3 (es) | 2022-02-22 |
EP3560495A1 (en) | 2019-10-30 |
CN110114069A (zh) | 2019-08-09 |
EP3560495B1 (en) | 2021-07-28 |
CN110114069B (zh) | 2022-03-04 |
TW201828920A (zh) | 2018-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6685432B2 (ja) | マイクロニードルデバイス | |
EP2540337A1 (en) | Micro-needle device and preparation method | |
US7455654B2 (en) | Method and apparatus for reducing the incidence of tobacco use | |
JP2006500974A (ja) | 被覆され微細突起物を有する経皮的薬物送達装置 | |
CA3073442C (en) | Method of rapidly achieving therapeutic concentrations of zolmitriptan for treatment of migraines and cluster headaches | |
US9849170B2 (en) | Microneedle coating composition and microneedle device | |
JPWO2012115208A1 (ja) | マイクロニードルデバイス用glp−1アナログ組成物 | |
WO2018155431A1 (ja) | マイクロニードルデバイス | |
US20200000712A1 (en) | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches | |
WO2008115586A1 (en) | Apparatus and method for transdermal delivery of a triptan agonist | |
JP7430140B2 (ja) | マイクロニードルデバイス及びそれを製造する方法 | |
KR102507674B1 (ko) | 마이크로 니들 디바이스 및 그것을 제조하는 방법 | |
MXPA06004719A (en) | Method and apparatus for reducing the incidence of tobacco use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200324 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200331 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6685432 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |